MANHATTAN, Kan., Dec. 6, 2017 /PRNewswire/ -- Earlier this week NPR ran a story on gene therapy showing promise for a growing list of diseases. Libella Gene Therapeutics is excited to announce an experimental research project using gene therapy to treat and ultimately cure Alzheimer's Disease. Every day 228 Americans die from Alzheimer's, and there is currently no known treatment or cure for the disease.
The experimental research project will treat a limited number of patients using gene therapy treatment to lengthen telomeres. Dr. Bill Andrews and Libella Gene Therapeutics believe the lengthening telomeres is the key to treating and possibly curing Alzheimer's Disease. Libella Gene Therapeutics' delivery system has been demonstrated as safe, with minimal adverse reactions in over 186 clinical trials.
On why they decided to go the experimental research project route, Libella Gene Therapeutics President Dr. Jeff Mathis said, "Traditional clinical research trials can take years and millions—or even billions—of dollars. The research and techniques that have been proven to work are ready now."
The experimental research project is prepping to begin in the next few weeks and will be conducted in partnership with MediHelp in Cartagena, Colombia. For more information on participating in this experimental research project, please visit www.libellagenetherapeutics.com.
About Libella Gene Therapeutics
Our mission is to reverse aging and cure all age-related diseases, starting with Alzheimer's. Libella Gene Therapeutics has exclusively licensed the technology of Sierra Sciences and Dr. Bill Andrews to conduct a human research project. We believe we have the scientist, the technology, the physicians, and the lab partners that are necessary to get this done. By activating telomerase, we hope to lengthen telomeres in the body's cells. To have an effective delivery system for the telomerase to reach every cell in the body, quadrillions of gene therapy particles must be produced for each test subject. The production of enough gene therapy particles to treat one person takes anywhere from four months to a year to complete. Because of the demands on production, we will have a limited number of tests available. We anticipate having around 50 spots over the next 12 months.
About Dr. Bill Andrews
Since 1981, Bill Andrews has focused on finding ways to extend the human life span and health span through telomere maintenance. As one of the principal discoverers of both the RNA and protein components of human telomerase, Dr. Andrews was awarded second place as "National Inventor of the Year" in 1997. He earned his Ph.D. in molecular and population genetics at the University of Georgia in 1981. He has served as Senior Scientist at Armos Corporation and Codon Corporation, Director of Molecular Biology at Berlex Biosciences and Geron Corporation, and Director of Technology Development at EOS Biosciences. He is also a named inventor on over 50 US-issued patents on telomerase and the author of numerous scientific research studies published in peer-reviewed scientific journals. Dr. Andrews has been featured in Popular Science, on the Today show, and in numerous documentaries.
Learn more about the 186 successful clinical trials : http://www.abedia.com/wiley/vectors.php
Read the recent NPR gene therapy story: https://www.npr.org/sections/health-shots/2017/11/29/565728869/gene-therapy-shows-promise-for-a-growing-list-of-diseases
View original content:http://www.prnewswire.com/news-releases/libella-gene-therapeutics-announces-experimental-research-project-in-hopes-of-reversing-alzheimers-300567791.html
SOURCE Libella Gene Therapeutics
Share this article